Network With Healthcare Investors at MedCity INVEST 2024!
The conference, scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, brings together healthcare investors, startups, and innovative-minded executives. Register today!
The conference, scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, brings together healthcare investors, startups, and innovative-minded executives. Register today!
Are you a biopharma startup focused on oncology? A devices /diagnostics startup focused on cardiology? Or a health tech startup focused on how consumers/employers are addressing women’s health? If so, submit an application for MedCity INVEST Pitch Perfect by February 29!
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The conference, scheduled for May 21-22 at the Ritz Carlton in Chicago, is the premier boutique healthcare investment event in the U.S.
Equal parts networking and curated panels covering the latest trends in healthcare investment, MedCity INVEST 2024 is the ideal event to discuss health tech, biopharma, devices and diagnostics investment opportunities. Register today!
Versant Ventures-backed Firefly Bio is part of a growing group of companies developing degrader antibody conjugates, or DACs. These targeted cancer therapies combine properties of antibody drug conjugates and protein degraders in order to overcome limitations of both types of therapies.
The conference is the premier boutique healthcare investment event in the U.S.
Cour Pharmaceuticals’ nanoparticles reprogram the immune system to stop inflammation behind autoimmune disease. Three big pharma companies joined the startup’s Series A financing, which will fund clinical trials in type 1 diabetes and myasthenia gravis.
Check out news from Health Wildcatters, Rivia Health, Apella, and more.
Check out news from Alpha Sophia, Wisedocs, Swift Medical, and Isaac Health.
Sanofi and Synthekine will work together to develop cytokine therapies for inflammatory diseases. This new alliance comes as Sanofi is salvaging a different cytokine therapy that showed disappointing efficacy in Phase 2 after the pharma giant acquired it in a $2.5 billion deal.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
In response to emailed questions, Kismet Health Co-founders CEO Dr. Cierra Gromoff and COO Christie Sander talked about why they started the business.
Startup TrX1 develops cell therapies that function like a particular type of regulatory T cell, or Treg, whose role includes dampening inflammation and inducing long-term tolerance. Based on research from Stanford, TrX1’s lead program is a potential therapy for preventing graft-versus-host disease.
Each track will spotlight a different specialty area including: oncology, cardiology, women's health and preventing burnout/supporting operational efficiency.
Check out news from Kismet Health, the University of California at Berkeley's life science startups, and the companies presenting at the Consumer Technology Association's pitch contest at CES.
Goldman Sachs’s new fund—its first dedicated to life sciences—will focus on early- to mid-stage therapeutics companies with multiple assets. Genetic medicine, cell therapy, immunotherapy, and artificial intelligence are among the areas of investment interest for the firm.